...
search icon
mgtx-img

MeiraGTx Holdings PLC, Common Stock

MGTX

NSQ

$5.41

+$0.09

(1.69%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$410.05M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
0
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.22
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$3.85 L
$8.75 H
$5.41

About MeiraGTx Holdings PLC, Common Stock

MeiraGTx Holdings plc, a clinical stage genetics medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia. It is also developing AAV-AQP1 in Phase 2 trial for radiation-induced grade 2/3 radiation-induced xerostomia, as well as in Phase ½ trial for Sjogren's syndrome; AAV-GAD in Phase 2 trial for Parkinson's disease; AAV-RPE65 in Phase 2 trial for RPE65-associated retinal dystrophy; and AAV-CNGB3 and AAV-CNGA3, which are both in Phase 2 trial for achromatopsia, as well as offers AAV-AIPL1 for Leber congenital amaurosis (LCA) 4. In addition, the company's products under preclinical development include AAV-RDH12 for retinol dehydrogenase 12 mutation-associated retinal dystrophy; AAV-BBS10 for Bardet-Biedl syndrome (BBS) due to BBS10 mutations; AAV-RetGC for LCA type 1; and AAV-UPF1 for amyotrophic lateral sclerosis, as well as programs for Alzheimer's disease, and wet and dry neovascular age related macular degeneration. Further, it provides riboswitch platform for the delivery of metabolic peptides; and cell therapies for oncology, autoimmune disease, and long term intractable pain. The company has collaborations with Johnson & Johnson Innovative Medicine for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease; and Hologen Limited for the research, development, manufacture, and commercialization of AAV-GAD investigational gene therapy for the treatment of Parkinson's disease, AAV-BDNF investigational gene therapy for genetic obesity disorders, and other genetic medicines to the central nervous system. MeiraGTx Holdings plc was founded in 2015 and is based in New York, New York. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameMGTXSectorS&P500
1-Week Return6.71%0.44%0.24%
1-Month Return-31.26%-7.69%-7.32%
3-Month Return-13.58%-3.35%-12.05%
6-Month Return-8.92%-11.09%-9.73%
1-Year Return3.05%-2.13%5.05%
3-Year Return-56.86%-1.18%20.03%
5-Year Return-62.92%34.44%83.31%
10-Year Return-63.93%84.87%153.54%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue15.56M37.70M15.92M14.02M33.28M[{"date":"2020-12-31","value":41.28,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":42.23,"profit":true},{"date":"2023-12-31","value":37.18,"profit":true},{"date":"2024-12-31","value":88.27,"profit":true}]
Cost of Revenue-7.87M8.72M13.73M23.79M[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":33.09,"profit":true},{"date":"2022-12-31","value":36.67,"profit":true},{"date":"2023-12-31","value":57.71,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Gross Profit15.56M29.83M7.20M14.02M9.49M[{"date":"2020-12-31","value":52.18,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":24.13,"profit":true},{"date":"2023-12-31","value":46.99,"profit":true},{"date":"2024-12-31","value":31.81,"profit":true}]
Gross Margin100.00%79.12%45.21%100.00%28.51%[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":79.12,"profit":true},{"date":"2022-12-31","value":45.21,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":28.51,"profit":true}]
Operating Expenses78.12M110.89M132.28M151.08M173.70M[{"date":"2020-12-31","value":44.97,"profit":true},{"date":"2021-12-31","value":63.84,"profit":true},{"date":"2022-12-31","value":76.15,"profit":true},{"date":"2023-12-31","value":86.98,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Income(62.55M)(73.19M)(116.36M)(137.06M)(164.21M)[{"date":"2020-12-31","value":-6255441700,"profit":false},{"date":"2021-12-31","value":-7319200000,"profit":false},{"date":"2022-12-31","value":-11635500000,"profit":false},{"date":"2023-12-31","value":-13706100000,"profit":false},{"date":"2024-12-31","value":-16421200000,"profit":false}]
Total Non-Operating Income/Expense5.70M(6.45M)(17.43M)42.50M7.29M[{"date":"2020-12-31","value":13.41,"profit":true},{"date":"2021-12-31","value":-15.17,"profit":false},{"date":"2022-12-31","value":-41.01,"profit":false},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":17.16,"profit":true}]
Pre-Tax Income(57.99M)(79.56M)(129.62M)(84.03M)(147.79M)[{"date":"2020-12-31","value":-5799200400,"profit":false},{"date":"2021-12-31","value":-7956100000,"profit":false},{"date":"2022-12-31","value":-12961500000,"profit":false},{"date":"2023-12-31","value":-8402700000,"profit":false},{"date":"2024-12-31","value":-14779100000,"profit":false}]
Income Taxes(4.03M)(7.58M)13.26M13.56M-[{"date":"2020-12-31","value":-29.73,"profit":false},{"date":"2021-12-31","value":-55.93,"profit":false},{"date":"2022-12-31","value":97.77,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Income After Taxes(53.96M)(71.98M)(142.88M)(97.59M)-[{"date":"2020-12-31","value":-5395958100,"profit":false},{"date":"2021-12-31","value":-7197600000,"profit":false},{"date":"2022-12-31","value":-14287500000,"profit":false},{"date":"2023-12-31","value":-9758910500,"profit":false},{"date":"2024-12-31","value":"-","profit":true}]
Income From Continuous Operations(57.99M)(79.56M)(129.98M)(131.56M)(147.79M)[{"date":"2020-12-31","value":-5799200400,"profit":false},{"date":"2021-12-31","value":-7956100000,"profit":false},{"date":"2022-12-31","value":-12997600000,"profit":false},{"date":"2023-12-31","value":-13155500000,"profit":false},{"date":"2024-12-31","value":-14779100000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(53.96M)(71.98M)(142.88M)(84.03M)(147.79M)[{"date":"2020-12-31","value":-5395958100,"profit":false},{"date":"2021-12-31","value":-7197600000,"profit":false},{"date":"2022-12-31","value":-14287500000,"profit":false},{"date":"2023-12-31","value":-8402700000,"profit":false},{"date":"2024-12-31","value":-14779100000,"profit":false}]
EPS (Diluted)(1.54)(1.81)(2.89)(2.31)(2.13)[{"date":"2020-12-31","value":-154,"profit":false},{"date":"2021-12-31","value":-181,"profit":false},{"date":"2022-12-31","value":-289,"profit":false},{"date":"2023-12-31","value":-231,"profit":false},{"date":"2024-12-31","value":-213,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

MGTX
Cash Ratio 1.71
Current Ratio 2.03
Quick Ratio 2.03

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

MGTX
ROA (LTM) -34.41%
ROE (LTM) -143.48%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

MGTX
Debt Ratio Lower is generally better. Negative is bad. 0.75
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.25

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

MGTX
Trailing PE NM
Forward PE 36.10
P/S (TTM) 12.82
P/B 6.29
Price/FCF NM
EV/R 12.25
EV/Ebitda NM

FAQs

What is MeiraGTx Holdings PLC share price today?

MeiraGTx Holdings PLC (MGTX) share price today is $5.41

Can Indians buy MeiraGTx Holdings PLC shares?

Yes, Indians can buy shares of MeiraGTx Holdings PLC (MGTX) on Vested. To buy MeiraGTx Holdings PLC from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in MGTX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of MeiraGTx Holdings PLC be purchased?

Yes, you can purchase fractional shares of MeiraGTx Holdings PLC (MGTX) via the Vested app. You can start investing in MeiraGTx Holdings PLC (MGTX) with a minimum investment of $1.

How to invest in MeiraGTx Holdings PLC shares from India?

You can invest in shares of MeiraGTx Holdings PLC (MGTX) via Vested in three simple steps:

  • Click on Sign Up or Invest in MGTX stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in MeiraGTx Holdings PLC shares
What is MeiraGTx Holdings PLC 52-week high and low stock price?

The 52-week high price of MeiraGTx Holdings PLC (MGTX) is $8.75. The 52-week low price of MeiraGTx Holdings PLC (MGTX) is $3.85.

What is MeiraGTx Holdings PLC price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of MeiraGTx Holdings PLC (MGTX) is 6.29

What is the Market Cap of MeiraGTx Holdings PLC?

The market capitalization of MeiraGTx Holdings PLC (MGTX) is $410.05M

What is MeiraGTx Holdings PLC’s stock symbol?

The stock symbol (or ticker) of MeiraGTx Holdings PLC is MGTX

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top